Targeting the RNA-binding protein Staufen1 with FDA-approved drugs to prevent skeletal muscle atrophy
Description: Muscle atrophy is a condition characterized by the shrinking and weakening of muscles impacting everyday activities. It can occur during extended periods in space due to reduced gravity, as well as in various conditions on Earth, including inactivity, aging, injuries, and diseases. In previous research, the research team identified a protein called Staufen1 that plays a key role in the early stages of muscle atrophy across various conditions, including ground-based human and mouse models of microgravity. Their current research aims to determine if muscle atrophy can be reduced or prevented by modulating Staufen1 levels. In addition, they aim to identify FDA-approved drugs targeting Staufen1. The results of this study have the potential to accelerate the development of new treatments and countermeasures to effectively combat muscle atrophy in diverse conditions.
Funder: Canadian Space Agency
Amount: CA$180,000
Funding type: research
Funder scheme: Class Grant and Contribution Program to Support Research, Awareness and Learning in Space Science and Technology
Start date: 2025-01-01
End date: 2027-12-31
Institution: University of Ottawa
Funded outputs count: 0
Funder award ID: 003-2025-2026-Q2-00089
OpenAlex ID: G7630637765